Kronos Bio (Kronos Bio) Net Margin % : -1,107.61% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Kronos Bio Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Kronos Bio's Net Income for the three months ended in Dec. 2023 was $-25.32 Mil. Kronos Bio's Revenue for the three months ended in Dec. 2023 was $2.29 Mil. Therefore, Kronos Bio's net margin for the quarter that ended in Dec. 2023 was -1,107.61%.

The historical rank and industry rank for Kronos Bio's Net Margin % or its related term are showing as below:

KRON' s Net Margin % Range Over the Past 10 Years
Min: -1791.87 Med: -1791.87 Max: -1791.87
Current: -1791.87

KRON's Net Margin % is ranked worse than
79.36% of 1027 companies
in the Biotechnology industry
Industry Median: -162.84 vs KRON: -1791.87

Kronos Bio Net Margin % Historical Data

The historical data trend for Kronos Bio's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kronos Bio Net Margin % Chart

Kronos Bio Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Margin %

Get a 7-Day Free Trial

-1,791.87

Kronos Bio Quarterly Data
	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Margin %	Get a 7-Day Free Trial															-	-2,148.89	-1,595.55	-3,421.37	-1,107.61

Competitive Comparison of Kronos Bio's Net Margin %

For the Biotechnology subindustry, Kronos Bio's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kronos Bio's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kronos Bio's Net Margin % distribution charts can be found below:

* The bar in red indicates where Kronos Bio's Net Margin % falls into.

Kronos Bio Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Kronos Bio's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-112.673	/	6.288
	=	-1,791.87 %

Kronos Bio's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-25.32	/	2.286
	=	-1,107.61 %

Kronos Bio (NAS:KRON) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Kronos Bio Net Margin % Related Terms

Thank you for viewing the detailed overview of Kronos Bio's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Kronos Bio (Kronos Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kronos Bio Inc (NAS:KRON) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1300 So. El Camino Real, Suite 300, San Mateo, CA, USA, 94402

Website

https://www.kronosbio.com

Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.

Executives

Jorge Dimartino	officer: Chief Medical Officer & VP	C/O KRONOS BIO, INC., 1300 S, SAN MATEO CA 94402
Christopher Dinsmore	officer: Chief Scientific Officer	C/O KRONOS BIO, INC., 1300 EL CAMINO REAL, STE. 300, SAN MATEO CA 94402
Barbara Kosacz	officer: COO & General Counsel	3175 HANOVER STREET, PALO ALTO CA 94304
Norbert W Bischofberger	director, 10 percent owner, officer: President & CEO	333 LAKESIDE DR, C/O GILEAD SCIENCES, INC., FOSTER CITY CA 94404
Sandra A. Gardiner	officer: Interim CFO	CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005
Yasir B. Al-wakeel	officer: Chief Financial Officer	MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Roger D Dansey	director	21823 30TH DRIVE SE, BOTHELL WA 98021
Katherine V Stultz	director	C/O GRAPHITE BIO, INC., 279 EAST GRAND AVENUE, SUITE 430, SOUTH SAN FRANCISCO CA 94080
Backer Marianne De	director	177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105
Roshawn A. Blunt	director	11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130
Jakob Loven	director	C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVENUE, NEW HAVEN CT 06511
Taiyin Yang	director	2631 HANOVER STREET, PALO ALTO CA 94304
Otello Stampacchia	director, 10 percent owner	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
John C Martin	director	333 LAKESIDE DRIVE, FOSTER CITY X1 94404
Elena Ridloff	director	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130